id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
CMS-2018-0132-3946,CMS,CMS-2018-0132,Most Favored Nation Model,Rule,,2021-12-29T05:00:00Z,2021,12,2021-12-29T05:00:00Z,,2022-01-06T18:28:20Z,2021-28225,0,0,0900006484effbf6
CMS-2018-0132-3911,CMS,CMS-2018-0132,Most Favored Nation Model,Proposed Rule,,2021-08-10T04:00:00Z,2021,8,2021-08-10T04:00:00Z,2021-10-13T03:59:59Z,2021-10-13T01:01:22Z,2021-16886,0,0,0900006484c3b406
CMS-2018-0132-2750,CMS,CMS-2018-0132,Most Favored Nation Model,Rule,,2020-11-27T05:00:00Z,2020,11,2020-11-27T05:00:00Z,2021-01-27T04:59:59Z,2021-01-28T02:03:41Z,2020-26037,0,0,09000064849788ca
CMS-2018-0132-0001,CMS,CMS-2018-0132,Medicare Programs: International Pricing Index Model for Medicare Part B Drugs  (CMS-5528-ANPRM),Proposed Rule,,2018-10-30T04:00:00Z,2018,10,2018-10-30T04:00:00Z,2019-01-01T04:59:59Z,2019-01-02T02:02:16Z,2018-23688,0,0,0900006483868598